| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/12/2002 | EP1212314A1 Benzopyran derivative |
| 06/12/2002 | EP1212313A1 7-carboxy-flavone derivatives, preparation method and therapeutic use |
| 06/12/2002 | EP1212312A1 Novel derivatives of flavones, xanthones and coumarins |
| 06/12/2002 | EP1212311A1 Chalcone coumarins |
| 06/12/2002 | EP1212309A1 Caspase inhibitor |
| 06/12/2002 | EP1212306A2 Hydroxyalkanoylaminolactams and related structures as inhibitors of abeta protein production |
| 06/12/2002 | EP1212305A2 1,5-benzodiazepine derivatives as cck-a receptor agonists |
| 06/12/2002 | EP1212303A2 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 06/12/2002 | EP1212302A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 06/12/2002 | EP1212300A1 Azacycloalkanone serine protease inhibitors |
| 06/12/2002 | EP1212299A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 06/12/2002 | EP1212298A1 Isolation of natural l-beta-3-indolylalanine and enrichment of natural aliphatic amino acid mixtures with natural l-beta-3-indolylalanine |
| 06/12/2002 | EP1212297A1 4-amino-1-aryl-1,5-dihydro-pyrrole-2-one with anti-convulsive and anxiolytic properties and a method for producing the same |
| 06/12/2002 | EP1212296A1 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 06/12/2002 | EP1212295A1 SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
| 06/12/2002 | EP1212292A1 (-)-verbenone derivatives |
| 06/12/2002 | EP1212120A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| 06/12/2002 | EP1212119A1 Use of cyamemazine for cold turkey benzodiazepine treatment |
| 06/12/2002 | EP1212106A1 Phospholipid-coated implants |
| 06/12/2002 | EP1212101A1 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| 06/12/2002 | EP1212099A2 Amphiphilic prodrugs |
| 06/12/2002 | EP1212098A2 Enzyme inhibitors |
| 06/12/2002 | EP1212097A2 Enzyme inhibitors |
| 06/12/2002 | EP1212094A2 Delivery of antimicrobial toxins |
| 06/12/2002 | EP1212090A2 Pharmaceutical composition comprising an insulin sensitizer |
| 06/12/2002 | EP1212089A2 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonists |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212086A1 Immunological tolerance-induction agent |
| 06/12/2002 | EP1212085A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 06/12/2002 | EP1212081A2 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 06/12/2002 | EP1212077A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 06/12/2002 | EP1212076A2 Stimulation of sperm function |
| 06/12/2002 | EP1212071A1 Stable carotene-xanthophyll beadlet compositions and methods of use |
| 06/12/2002 | EP1212070A1 Plant extract mixtures and their uses |
| 06/12/2002 | EP1212069A2 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 06/12/2002 | EP1212068A1 Method of enhancing the efficacy of anti-tumor agents |
| 06/12/2002 | EP1212067A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 06/12/2002 | EP1212066A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids |
| 06/12/2002 | EP1212065A1 Compositions and methods for raising hdl cholesterol levels |
| 06/12/2002 | EP1212064A2 Use of inhibitors of endotoxin for the treatment of heart failure and of cachexia |
| 06/12/2002 | EP1212063A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 06/12/2002 | EP1212062A1 Use of thienopyrimidines |
| 06/12/2002 | EP1212061A1 Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol |
| 06/12/2002 | EP1212060A1 Use of nicotine or derivatives thereof in a medicine for treating neurological diseases, in particular parkinson disease |
| 06/12/2002 | EP1212059A1 Iron chelators and uses thereof |
| 06/12/2002 | EP1212058A1 Topical treatment for prevention of ocular infections |
| 06/12/2002 | EP1212057A1 Extended duration light activated cancer therapy |
| 06/12/2002 | EP1212056A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases |
| 06/12/2002 | EP1212055A1 Neurotherapeutic composition and method |
| 06/12/2002 | EP1212054A2 Azetidine compounds in cns and eye diseases |
| 06/12/2002 | EP1212053A1 Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| 06/12/2002 | EP1212052A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 06/12/2002 | EP1212051A1 Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
| 06/12/2002 | EP1212050A2 Formulations containing tetracyclinesfor treating or preventing mucositis |
| 06/12/2002 | EP1212049A2 Use of thiamphenicol for thetreatment of chlamydia pneumoniae infections |
| 06/12/2002 | EP1212048A1 Use of sigma receptor agonists for the treatment of depression |
| 06/12/2002 | EP1212047A2 Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| 06/12/2002 | EP1212046A2 Flushable disposable polymeric products |
| 06/12/2002 | EP1212041A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 06/12/2002 | EP1212040A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 06/12/2002 | EP1212039A1 Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
| 06/12/2002 | EP1212034A1 Enzyme inhibitors |
| 06/12/2002 | EP1212000A1 Method of controlling body temperature while reducing shivering |
| 06/12/2002 | EP1211955A1 A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| 06/12/2002 | EP1211942A1 Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution |
| 06/12/2002 | EP1211931A1 A knockout mouse for the tumor suppressor gene anx7 |
| 06/12/2002 | EP1128844A4 Methods for enhancing wound healing |
| 06/12/2002 | EP1105386B1 Novel salt form of pantoprazole |
| 06/12/2002 | EP1082107A4 Controlled release lipoic acid |
| 06/12/2002 | EP1068192B1 Novel crystalline complexes of baccatin iii with imidazole, 2-methylimidazole or isopropanol |
| 06/12/2002 | EP1061920B1 Pharmaceutical formulation comprising a 2[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation |
| 06/12/2002 | EP1056722B1 Bisulfate salt of hiv protease inhibitor |
| 06/12/2002 | EP1044000B1 Combination therapy for the treatment of aids |
| 06/12/2002 | EP1032571B1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists |
| 06/12/2002 | EP1028947B1 H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| 06/12/2002 | EP1023287B1 3-oxo-2(h)-1,2,4-triazine derivatives as ligands of 5ht1a receptors |
| 06/12/2002 | EP1023263B1 Novel vitamin d analogues |
| 06/12/2002 | EP1007059A4 Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria |
| 06/12/2002 | EP1005337A4 Pharmacologic drug combination in vagal-induced asystole |
| 06/12/2002 | EP0984778B1 Neuropeptide-y ligands |
| 06/12/2002 | EP0977484A4 Non-spherical and non-platelet pyrithione salts |
| 06/12/2002 | EP0969843B1 Antitussive compositions containing theobromine |
| 06/12/2002 | EP0968222B1 Novel erythromycin derivatives, method of preparation and application as medicines |
| 06/12/2002 | EP0966471B1 2-beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors |
| 06/12/2002 | EP0966437B1 5-aroylnaphthalene derivatives |
| 06/12/2002 | EP0966274B1 Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
| 06/12/2002 | EP0948357B1 Use of low molecular weight amino alcohols in ophthalmic compositions |
| 06/12/2002 | EP0939655B1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 06/12/2002 | EP0934080B1 1,3-bis-(n-lactamyl) propane and the pharmaceutical and cosmetic use thereof |
| 06/12/2002 | EP0929517B1 Hydroxamic acid derivatives |
| 06/12/2002 | EP0928193B1 Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
| 06/12/2002 | EP0888327B1 Benzopyran derivatives having leukotriene-antagonistic action |
| 06/12/2002 | EP0885221B1 Azabicyclic esters of carbamic acids useful in therapy |
| 06/12/2002 | EP0885210B1 Tricylic compounds having binding affinity for melatonin receptors, their production and use |
| 06/12/2002 | EP0885204B1 Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds |
| 06/12/2002 | EP0881901B1 New associations of active principles containing clopidogrel and an antithrombotic agent |
| 06/12/2002 | EP0880540B1 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase |
| 06/12/2002 | EP0880533B1 Triazole derivatives useful in therapy |
| 06/12/2002 | EP0877739B1 Azole compounds endowed with antimycotic activity for human and veterinary use |
| 06/12/2002 | EP0876158B1 Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms |